Get the Stockscreener App
1.82
1.09%
-0.02
After Hours:
1.83
0.01
+0.55%
iBio Inc stock is traded at $1.82, with a volume of 1.10M.
It is down -1.09% in the last 24 hours and up +8.33% over the past month.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
See More
Previous Close:
$1.84
Open:
$1.89
24h Volume:
1.10M
Relative Volume:
1.09
Market Cap:
$90.41M
Revenue:
$300.00K
Net Income/Loss:
$-27.61M
P/E Ratio:
-3.1504
EPS:
-0.5777
Net Cash Flow:
$-22.17M
1W Performance:
+21.33%
1M Performance:
+8.33%
6M Performance:
+51.67%
1Y Performance:
+122.49%
1-Day Range:
$1.80
$1.91
1-Week Range:
$1.509
$2.00
52-Week Range:
$0.5562
$3.82
iBio Inc Stock (IBIO) Company Profile
Name
iBio Inc
Sector
Industry
Phone
302-355-0650
Address
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
1.82 | 91.41M | 300.00K | -27.61M | -22.17M | -0.5777 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Oppenheimer | Outperform |
| Oct-17-25 | Initiated | Leerink Partners | Outperform |
| May-28-24 | Initiated | Chardan Capital Markets | Buy |
| Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
| Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-20 | Initiated | Alliance Global Partners | Buy |
View All
iBio Inc Stock (IBIO) Latest News
Top iBio (IBIO) Competitors 2026 - MarketBeat
iBio (IBIO) director receives 60,000 stock options vesting over 3 years - Stock Titan
Logos Global reports zero ownership in iBio (NASDAQ: IBIO) - Stock Titan
Point72, Steven A. Cohen report 0% in iBio (IBIO) amendment - Stock Titan
EcoR1 and Oleg Nodelman report 1.58M shares in iBio (NASDAQ: IBIO) - Stock Titan
Cormorant (IBIO) reports 3.83M shares, holds near-10% via warrants - Stock Titan
Leerink Partners Maintains IBio Inc(IBIO.US) With Buy Rating, Raises Target Price to $6 - Moomoo
iBio (NASDAQ: IBIO) — Sirenia/Manager report 11.59M shares, near 10% cap - Stock Titan
Elizabeth Stoner joins iBio (IBIO) board and files initial Form 3 - Stock Titan
We're Not Very Worried About iBio's (NASDAQ:IBIO) Cash Burn Rate - Yahoo Finance
IBIO Should I Buy - Intellectia AI
iBio (IBIO) adviser and manager report a 9.99% beneficial stake - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail
Insider Traders Lose US$19k As iBio Drops - simplywall.st
iBio, Inc. Stock 12‑Month Price Target Raised to $5.53, Implies 244% Upside - TradingView
IBio 3Q Rev $0.00 >IBIO - Moomoo
Intelligent Bio Solutions Reports 46% Revenue Growth in Q3 FY202 - GuruFocus
IBIO Achieves Key Milestones in Obesity Treatment Development - GuruFocus
IBio reports Q3 fiscal year 2026 financial results and provides corporate update - marketscreener.com
iBio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Frazier funds disclose holdings and warrants in iBio (NASDAQ: IBIO) - Stock Titan
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update - The Manila Times
IBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com
iBio (IBIO) raises $74.8M in cash and investments while net loss reaches $22.4M - Stock Titan
iBio (Nasdaq: IBIO) widens Q3 loss, boosts cash to fund pipeline into 2028 - Stock Titan
IBio Extends Cash Runway Into 4Q of Fiscal Yr 2028 - Moomoo
TradingKey - TradingKey
Number of shareholders of iBio, Inc. – NASDAQ:IBIO - TradingView
IBIO Stock Price, Quote & Chart | IBIO INC (NASDAQ:IBIO) - ChartMill
MSN Money - MSN
iBio Inc. (IBIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
iBio Strengthens Board with Appointment of Dr. Stoner - TipRanks
Veteran biotech executive joins iBio (NASDAQ: IBIO) board as Class II director - Stock Titan
iBio Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
iBio appoints Elizabeth Stoner to board of directors By Investing.com - Investing.com Australia
iBio appoints Elizabeth Stoner to board of directors - Investing.com
iBio, Inc. Appoints Dr. Elizabeth Stoner to Board of Directors - Quiver Quantitative
iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors - The Manila Times
Biotech veteran Elizabeth Stoner joins iBio board ahead of first human trial - Stock Titan
iBio, Inc. (NASDAQ:IBIO) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
iBio (NASDAQ: IBIO) substitutes SILV Fund after 876,340‑share transfer - Stock Titan
IBIO stock is soaring today after iBio's muscle-preserving drug receives approval for human trial in Australia - MSN
IBIO (IBIO) price target increased by 18.73% to 5.47 - MSN
iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600 - Yahoo Finance
10 Best NASDAQ Growth Stocks to Buy and Hold Forever - Insider Monkey
IBIO (iBio Inc.) falls 2.37% today after Q1 2026 EPS lands slightly below consensus estimates.Revenue Guidance - Xã Châu Thành
IBIO (iBio Inc.) reports 77.8 percent year over year Q1 2026 revenue growth, shares edge higher.Growth Acceleration - Cổng thông tin điện tử Tỉnh Sơn La
iBio, Inc. 8-K/A Filing Details: Company Information, Address, and Stock Listing (April 8, 2026) - Minichart
iBio Inc Stock (IBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):